Trial result ·
Secukinumab for Giant Cell Arteritis.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This trial tested secukinumab in people with giant cell arteritis. Steroids are the usual treatment for this disease. Many people on steroids have flares or harm from the drug. This was a phase 3 trial run at many sites. People were put into groups by chance. Neither they nor their doctors knew who got which drug. Groups got 300 mg or 150 mg of secukinumab, or a dummy drug. The secukinumab groups cut down steroids over 26 weeks. The dummy group cut down steroids over 52 weeks.
What they found
In total, 140 people got 300 mg, and 98 got 150 mg. Another 115 people got the dummy drug. The main goal was lasting control of the disease at week 52. More people on 300 mg reached this goal than on the dummy drug. But the gap was not clear enough to rule out chance. The 150 mg dose gave a result close to the dummy drug. Side effects were common in all groups. Serious side effects were reported less often in both secukinumab groups. Serious infections were seen more often with 150 mg than in other groups.
What it means for patients
The authors say the 300 mg group did not clearly differ from the dummy group. This compared a 26-week steroid cut-down with a 52-week one. So this trial did not show a clear gain from secukinumab at week 52.
Why it is not certain yet
The small gain seen with 300 mg could be due to chance. The trial plan changed partway through. Only 19 people joined the dummy group before that change. The abstract does not say if gaps in side effects were due to chance. The results cover only 52 weeks of treatment.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Secukinumab for Giant Cell Arteritis.
PubMed · PMID 42234457We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Giant cell arteritis publications